Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting now · Phase 2

Conditions studied: Metastatic Castration-resistant Prostate Cancer

In brief

Despite improvements in treatment, metastatic prostate cancer remains incurable, especially in the case of pretreated metastatic castration-resistant disease (mCRPC), where treatment options are limited, leading to an unmet need. The paradigm shift in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has affected the treatment landscape for mCRPC patients. Many have already received androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI), making first-line mCRPC treatment challenging. The Swiss Group for Clinical Cancer Research (SAKK) has shown in previous studies that maintenance treatment with an ARPI, such as darolutamide, can improve radiographic progression-free survival (rPFS) in pretreated mCRPC patients. In the SAKK 08/16 trial, darolutamide maintenance was found to prolong PFS compared to placebo, especially in patients who responded well to prior ARPI treatment. Based on these findings, the hypothesis is that continued AR-pathway blockade with darolutamide, initiated in patients progressing from mHSPC to mCRPC on ARPI treatment, can improve outcomes when added to standard first-line mCRPC therapy and continued as maintenance. The proposed study aims to evaluate the efficacy of darolutamide, combined with physician-choice standard of care (including taxane chemotherapy, olaparib, radium 223, or LuPSMA), followed by maintenance therapy, on rPFS for patients in the first-line setting of mCRPC.

Key facts

Study ID

NCT06401980

Run by

Swiss Cancer Institute

People needed

162

Starts

2024-10-22

Expected to finish

2030-09-01

Last updated by the study team

2026-07-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent according to Swiss law and ICH GCP E6(R2) regulations before registration and prior to any trial specific procedures
• Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate
• Castration resistance: tumor progression after orchiectomy or during treatment with GnRH analogues (agonists or antagonists).
• Non-surgically castrated patient agrees on ongoing use of GnRH analogues (agonists or antagonists) during the trial
• Metastatic disease, documented by imaging according to PCWG3 criteria
• Measurable disease or bone lesions that are evaluable according to PCWG3 criteria
• A minimum of 12 months on ADT+ARPI therapy (calculated from ADT initiation) within mHSPC setting, showing an at least 50% PSA response or partial remission according to RECIST v1.1. ARPI change within mHSPC is only allowed for intolerance.
• Progressive disease according to modified PCWG3 before registration is defined as (at least 2 out of 3):
• PSA progression ≥ 25% above nadir (2 consecutive rises at least 3 weeks apart)
• New metastatic lesion on imaging (at least two or more new bone lesions on bone scan or one new non-bone lesion or progression on PSMA-PET/CT according to PROMISE V2 criteria
• Clinical progression
• Patients with a previously treated malignancy are eligible, when the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low
• Age ≥ 18 years
• WHO performance status 0-2
• Adequate bone marrow function: absolute neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 100 x 109/L, hemoglobin ≥ 90 g/L.
• Adequate hepatic function: total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert's disease ≤ 3.0 x ULN), ALT and AST ≤ 2.5 x ULN, or ≤ 5 x ULN under the assumption that abnormal values are a result of cancer
• Adequate renal function: estimated glomerular filtration rate (eGFR) > 30 mL/min/1.73 m2 (according to CKD-EPI formula)
• Men agree not to donate sperm or to father a child during trial treatment and until 3 months after the last dose of trial treatment
• Patients are able and willing to swallow darolutamide as whole tablet.

You may not qualify if…

• Presence of a small cell component
• Prior systemic therapy for metastatic castration-resistant disease
• Prior chemotherapy for mHSPC, except docetaxel
• Prior LuPSMA or radium 223 for prostate cancer
• Concomitant or recent (within 28 days of registration) treatment with any other experimental drug
• Concomitant use of other anti-cancer drugs or radiotherapy except for local pain control and GnRH analogues
• Severe or uncontrolled cardiovascular disease
• Acute exacerbations of chronic illnesses, serious infections, or major surgery within 28 days before expected start of treatment
• Clinical or radiological evidence of current spinal cord compression
• Any concomitant drugs contraindicated for use with darolutamide according to the approved product information
• Known hypersensitivity to darolutamide
• Known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of darolutamide
• Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Where it is running

• UniversitaetsSpital Zuerich — Zurich, Switzerland (enrolling)
• Kantonsspital Baden — Baden, Switzerland (enrolling)
• Istituto Oncologico della Svizzera Italiana (IOSI) — Bellinzona, Switzerland (enrolling)
• Inselspital — Bern, Switzerland (enrolling)
• Kantonsspital Graubuenden — Chur, Switzerland (enrolling)
• Hôpitaux Universitaires Genève HUG — Geneva, Switzerland (enrolling)
• Centre Hospitalier Universitaire Vaudois CHUV — Lausanne, Switzerland (enrolling)
• Luzerner Kantonsspital — Lucerne, Switzerland (enrolling)
• Kantonsspital St. Gallen — Sankt Gallen, Switzerland (enrolling)
• Kantonsspital Winterthur — Winterthur, Switzerland (enrolling)
• Tumorzentrum Aarau TZA — Aarau, Switzerland (enrolling)
• Stadtspital Triemli Zürich — Zurich, Switzerland (enrolling)
• OnkoZentrum Zürich - Standort Seefeld — Zurich, Switzerland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.